Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINISH-HL: First-Line Nivolumab-Guided Immunochemotherapy in Advanced Hodgkin Lymphoma
NCT07209059Phase 2Recruiting
- Sponsor
- National Medical Research Center for Hematology
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in classical Hodgkin lymphoma (cHL), sponsored by National Medical Research Center for Hematology. Started Jul 2025; status: recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT07209059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209059.